Added benefit of Mitsubishi Tanabe's colestilan not proven, says German IQWiG

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether Japanese drugmaker Mitsubishi Tanabe’s (TYO: 4508) BindRen (colestilan) offers added benefit over current standard therapy for patients with chronic renal failure who receive hemodialysis or peritoneal dialysis.

Patients for whom calcium- and aluminium-based phosphate binders are not an option have lesser benefit from colestilan than from sevelamer hydrochloride: In the key study, they discontinued treatment more frequently because of side effects, the IQWiG said. An added benefit is not proven in patients without this contraindication because the drug manufacturer did not present any relevant studies. BindRen was approved in Germany in January this year.

G-BA specified appropriate comparator therapy